|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
Hypertension is associated with increased expression of FABP3, FAS, FN1, IL1R2, LPL, SERPINE1, TGFB1, and VCAM1 and decreased expression of SELPLG and SERPINEB2.
|
23337395 |
2014 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis.
|
30160528 |
2018 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
A model with components of MetS explained only 12% of variability on PAI-1 levels (<i>R</i><sup>2</sup> = 0.12; <i>p</i> = 0.001), with <i>β</i> = 0.18 (<i>p</i> = 0.03) for hypertension, <i>β</i> = -0.16 (<i>p</i> = 0.05) for NL HDL-c, and <i>β</i> = 0.15 (<i>p</i> = 0.05) for NL triglycerides.<i>Conclusion</i>.
|
28271069 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development.
|
31356402 |
2019 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Although Angiotensin II-induced hypertension was blunted in PAI-1<sup>-/-</sup> mice, cardiac hypertrophy was accelerated.
|
28588076 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Analysis using categorical PAI-1 (in tertiles) showed that participants in the highest tertile (≥58 ng/ml) had 63% increased risk for hypertension [OR = 1.63 (1.12-2.37)] compared with those in the lowest tertile (<33 ng/ml).
|
28379891 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p < 0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p < 0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p < 0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p < 0.05), were independent risk factors for CRVO.
|
11583306 |
2001 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Considering cardiovascular diseases there is a number of genes involved in lipid metabolism (apolipoproteins, lipoprotein receptors, lipolytic enzymes), thrombosis/hemostasis (platelet receptors, pro- and anticoagulant proteins, fibrinogen, PAI's), hypertension (angiotensin converting enzyme, angiotensinogen) glucose metabolism (glucose transporters, enzymes) and obesity (hormones, receptors), that are interesting candidates for sophisticated genetic risk assessment.
|
9654602 |
1998 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
CTD_human |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
|
21051829 |
2010 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
Furthermore, increased plasma PAI-1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension.
|
10867719 |
2000 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
In 38 normotensive subjects with a family history of hypertension (relatives) and in 46 sex, age and body mass index matched controls with no family history of hypertension, tissue-type plasminogen activator (t-PA), plasminogen activator-inhibitor (PAI-1), D-dimer (DD) and prothrombin fragment 1+2 (F1+2) were evaluated.
|
11317134 |
2001 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
In conclusion, no association was found between M235T polymorphism and insulin resistance or PAI-1 levels, but results indicate relationship between I/D polymorphism of the ACE gene and plasma PAI-1 levels in the early stage of hypertension.
|
16981142 |
2006 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
In conclusion, the results indicated that the I/D polymorphism of the ACE gene was not related to plasma PAI-1 levels in a Chinese population with hypertension.
|
9524054 |
1998 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
|
15194475 |
2004 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Multivariate logistic regression analysis showed that PAI-1 4G/4G (P = 0.01) and the prevalence of hypertension (P < 0.0001) are independent risk factors of development of type 2 diabetic nephropathy.
|
10652041 |
2000 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
Patients with metabolic syndrome were characterized with increased body mass index (BMI), waist circumference, and HOMA-IR and HOMA-beta levels, and all had increased blood pressure and triglyceride levels, low high-density lipoprotein cholesterol levels, increased PAI-1 levels and reduced antioxidative defense levels.
|
17848118 |
2007 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Post-phlebotomy, PRA and PAI-1 responses were more dramatic, but the NO response less in normotensive subjects having a parental history of hypertension, suggesting that these changes may represent familial, possibly genetic influences before overt hypertension occurs.
|
19154322 |
2008 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol.
|
24189452 |
2014 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
LHGDN |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The T94G genotypes and plasma levels of adiponectin, and PAI-1 were determined in 568 Chinese patients, 212 with and 356 without hypertension, to study the possible associations of T94G genotype, plasma adiponectin, PAI-1 and blood pressure.
|
16741355 |
2007 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The aims of this study were to observe associations of the genetic polymorphism for PAI-1 and t-PA with hypertension and atherothrombotic stroke, and to elucidate whether impaired fibrinolytic activity in atherothrombotic stroke was related to atherothrombosis per se or to other risk factors such as hypertension.
|
11385207 |
2001 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
The following parameters were evaluated in 104 patients with previously untreated hypertension: plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) antigen, fibrinogen, D-dimer, and von Willebrand factor (vWF).
|
11054622 |
2000 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The functional plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism has previously been associated with hypertension.
|
21490692 |
2011 |